ALK and non-small cell lung carcinoma: In a retrospective study on non-small-cell lung cancer (NSCLC) patients undergoing either cytotoxic chemotherapy with platinum-based drugs or molecular targeted therapy with TKIs of EGFR or anaplastic lymphoma kinase, skeletal muscle loss was lower in patients receiving TKIs than in those receiving cytotoxic chemotherapy, suggesting that TKIs may be less prone to induce cancer cachexia than cytotoxic chemotherapy [73].